diazepam has been researched along with citalopram in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 3 (8.57) | 18.2507 |
| 2000's | 12 (34.29) | 29.6817 |
| 2010's | 19 (54.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Bojarski, AJ; Canale, V; Jastrzębska-Więsek, M; Kurczab, R; Lenda, T; Partyka, A; Satała, G; Wesołowska, A; Zajdel, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Gryboś, A; Głuch-Lutwin, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Więckowski, K | 1 |
| Gong, Q; Li, J; Li, X; Liu, W; Mao, F; Qiu, X; Wang, H; Wang, W; Xu, Y; Zhang, H; Zhang, J; Zhu, J | 1 |
| Kostowski, W; Płaźnik, A; Stefański, R | 1 |
| Sams-Dodd, F | 1 |
| Dekeyne, A; Girardon, S; Gobert, A; Millan, MJ | 1 |
| Kivistö, KT; Lapatto-Reiniluoto, O; Neuvonen, PJ | 1 |
| Juvonen, R; Korhonen, LE; Pelkonen, O; Raunio, H; Tolonen, A; Turpeinen, M; Uusitalo, J | 1 |
| Barberi, C; Danysz, W; Gravius, A; Schäfer, D; Schmidt, WJ | 1 |
| Bär, KJ; Beiderbeck, D; Boettger, MK; Jochum, T; Landgraf, R; Neumann, ID; Sauer, H; Wigger, A | 1 |
| Bortolato, M; Frau, R; Gessa, GL; Marrosu, F; Mereu, G; Orrù, M; Puligheddu, M | 1 |
| Birkett, MA; Kessler, EJ; Meyer, JS; Ritchie, S; Rowlett, JK; Shinday, NM | 1 |
| Baud, FJ; Beaune, S; Callebert, J; Juvin, P; Mégarbane, B; Risède, P | 1 |
| Gruca, P; Lason-Tyburkiewicz, M; Litwa, E; Papp, M; Willner, P | 1 |
| Lubszky, S; Reinhart, WH; Schulzki, T; Thöny, S | 1 |
| Hashimoto, S; Hattori, T; Kasahara, K; Kawakubo, H; Kawasaki, K; Nagatani, T; Nakazono, O; Takao, K; Tsujita, R | 1 |
| Marston, HM; Mitchell, EN; Nutt, DJ; Phelps, CE; Robinson, ES | 1 |
| Chourbaji, S; Lerch, S; Taylor, GT | 1 |
1 review(s) available for diazepam and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for diazepam and citalopram
| Article | Year |
|---|---|
Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram.
Topics: Adult; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Area Under Curve; Charcoal; Citalopram; Cross-Over Studies; Diazepam; Female; Gastric Lavage; Humans; Ibuprofen; Intestinal Absorption; Male; Selective Serotonin Reuptake Inhibitors | 1999 |
33 other study(ies) available for diazepam and citalopram
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
Topics: Amines; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Humans; Mice; Models, Molecular; Molecular Structure; Motor Activity; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2016 |
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonists; Drug Design; Humans; Indoles; Ligands; Models, Molecular; Pyridines; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists | 2017 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Depression; Drug Design; Ligands; Mice; Permeability; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship; Tacrine; Vilazodone Hydrochloride | 2018 |
Restraint stress-induced changes in saccharin preference: the effect of antidepressive treatment and diazepam.
Topics: Animals; Citalopram; Desipramine; Diazepam; Dose-Response Relationship, Drug; Electroshock; Food Preferences; Male; Rats; Rats, Inbred Strains; Restraint, Physical; Saccharin; Stress, Physiological; Time Factors | 1989 |
Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test.
Topics: Animals; Anti-Anxiety Agents; Citalopram; Diazepam; Drug Interactions; Hallucinogens; Interpersonal Relations; Male; Methadone; Motor Activity; Naloxone; Narcotic Antagonists; Narcotics; Phencyclidine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Social Isolation; Stereotyped Behavior | 1998 |
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
Topics: Animals; Biogenic Monoamines; Cerebral Cortex; Citalopram; Clozapine; Corpus Striatum; Diazepam; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; GABA Agents; Male; Norepinephrine; Nucleus Accumbens; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1999 |
Cytochrome P450 (CYP) inhibition screening: comparison of three tests.
Topics: Citalopram; Cytochrome P-450 Enzyme Inhibitors; Diazepam; Enzyme Inhibitors; Fluoxetine; Humans; Oxazepam; Propranolol; Sotalol | 2006 |
The role of group I metabotropic glutamate receptors in acquisition and expression of contextual and auditory fear conditioning in rats - a comparison.
Topics: Acoustic Stimulation; Animals; Avoidance Learning; Citalopram; Conditioning, Classical; Diazepam; Dizocilpine Maleate; Electroshock; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Fear; Freezing Reaction, Cataleptic; Hippocampus; Long-Term Potentiation; Male; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Scopolamine; Thiazoles | 2006 |
Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Crosses, Genetic; Diazepam; Disease Models, Animal; Hot Temperature; Male; Pain Threshold; Rats; Rats, Inbred Strains; Rats, Wistar; Reaction Time; Species Specificity; Statistics, Nonparametric | 2007 |
Sleep deprivation disrupts prepulse inhibition of the startle reflex: reversal by antipsychotic drugs.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Citalopram; Data Interpretation, Statistical; Diazepam; Hypnotics and Sedatives; Male; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation; Sleep, REM | 2008 |
Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Corticosterone; Diazepam; Drug Interactions; Fluoxetine; Male; Mice; Mice, Inbred BALB C; Selective Serotonin Reuptake Inhibitors | 2011 |
Mechanisms of high-dose citalopram-induced death in a rat model.
Topics: Animals; Body Temperature; Citalopram; Cyproheptadine; Diazepam; Dose-Response Relationship, Drug; Lethal Dose 50; Male; Rats; Rats, Sprague-Dawley; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Syndrome | 2012 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumazenil; GABA Modulators; Male; Mecamylamine; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Substance Withdrawal Syndrome; Substance-Related Disorders | 2014 |
Interaction of injectable neurotropic drugs with the red cell membrane.
Topics: Central Nervous System Agents; Chlorpromazine; Citalopram; Clomipramine; Clonazepam; Diazepam; Erythrocytes; Humans; Injections; Levetiracetam; Microscopy, Electron, Scanning; Neurotransmitter Agents; Phenobarbital; Phenytoin; Piracetam; Valproic Acid | 2014 |
The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cells, Cultured; Citalopram; Diazepam; Disease Models, Animal; Drug Synergism; Humans; Isoindoles; Male; Piperazines; Prefrontal Cortex; Pyridines; Pyrimidines; Rats; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Synaptic Transmission; Thiophenes | 2015 |
Psychopharmacological characterisation of the successive negative contrast effect in rats.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Buspirone; Carbolines; Citalopram; Diazepam; Dopamine Agents; Dopamine Antagonists; Emotions; Flupenthixol; GABA Antagonists; Male; Rats; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2015 |
Marble burying as compulsive behaviors in male and female mice.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Behavior, Animal; Citalopram; Compulsive Behavior; Diazepam; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Male; Mice; Mice, Inbred C57BL; Nesting Behavior; Sex Characteristics | 2017 |